This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Transurethral alprostadil

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

This treatment is effective in providing adequate erections

  • patients are told to void to make sure the urethra is moist
  • the pellet is inserted into the urethra via a small applicator and the penis massaged
  • in clinical practice only the higher dosages of 500 µg and 1000 µg are effective
  • erection occurs in under 10 minutes following insertion of transurethral alprostadil and lasts for 20-60 minutes
  • the incidence of priapism is lower than with intracavernosal alprostadil (1)
  • the long-term side effects and efficacy of transurethral alprostadil are uncertain
  • transurethral alprostadil is less invasive and less effective and works more slowly than injection therapy
  • side effects include:
    • penile pain (30-40%) and dizziness (2-10%)
    • urethral bleeding and urinary infection may result from faulty technique
    • urethral discomfort in patients with varicose veins
    • urethral and/or vaginal discomfort (1)
  • may be initiated by specialist for erectile dysfunction in patients where phosphodiesterase inhibitors are contraindicated

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.